Apple Watch largely does not detect or categorize AFib at a heart rate greater than 120 beats per minute, which may give some users a false sense of security
The success of the Apple Watch is unprecedented: In five short years, the Apple Watch has outsold the entire Swiss watch industry …
Context & Ripple Effects
The Apple Watch's health story has been built on validation studies: a UCSF–Cardiogram study claimed 97% AFib detection accuracy back in 2017, and the [[a:933462|FDA cleared the Series 4's heart features while mandating Apple label the risks of inaccurate readings]]. The Heart Study then showed how conservatively the alerting works in practice, flagging irregular pulses in only about 0.5% of 400K+ participants.
This report exposes the boundary of that system: above 120 bpm the watch largely stops detecting or categorizing AFib — precisely the state a racing heart during an episode presents. For a device positioned as the 'future of health' but which experts say has not yet changed patient management, the gap matters because reassurance, not data, is what most users take away.
First-order effects
- Users experiencing AFib alongside elevated heart rates get no alert or categorization from the watch, and the false-sense-of-security risk lands on exactly the people the feature was built to protect.
- Apple's exposure under its own FDA-mandated labeling grows: the required warnings about inaccurate readings now cover not just false positives but systematic blind spots at high heart rates.
Second-order effects
- Clinician skepticism hardens — with doctors already not accepting the watch into care workflows, an undetected-AFib window gives hospitals and cardiologists a concrete reason to keep treating it as a consumer gadget rather than a triage tool.
- Rival wearable makers gain a differentiation angle: validating arrhythmia detection across heart-rate ranges becomes a competitive claim against Apple's market-leading installed base.
Third-order effects
- If regulators treat this pattern as representative, consumer health wearables face pressure toward broader clinical validation across physiological extremes before marketing detection claims — the FDA's label-the-risks approach was the first step, and coverage gaps like this one argue for stricter pre-clearance evidence.
- The structural tension sharpens between consumer-device iteration speed and medical-device evidentiary standards: Apple can ship sensors to hundreds of millions of wrists, but each new health claim inherits liability for the conditions it silently misses.
The trend: Consumer wearables are crossing into regulated medical territory faster than their detection capabilities cover real-world physiology, forcing regulators and clinicians to police the gap between marketing and measurement.